HLA-G and lymphoproliferative disorders.

[1]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[2]  J. Dichgans,et al.  The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. , 2003, Brain : a journal of neurology.

[3]  R. Kiessling,et al.  IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. , 2002, The Journal of clinical investigation.

[4]  M. Bernard,et al.  Major histocompatibility complex abnormalities in non‐Hodgkin lymphomas , 2002, British journal of haematology.

[5]  P. J. van den Elsen,et al.  HLA-G Transactivation by cAMP-response Element-binding Protein (CREB) , 2002, The Journal of Biological Chemistry.

[6]  M. Weller,et al.  A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape1 , 2002, The Journal of Immunology.

[7]  J. Dausset,et al.  Human Leukocyte Antigen-G Expression After Heart Transplantation Is Associated With a Reduced Incidence of Rejection , 2002, Circulation.

[8]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[9]  J. Dausset,et al.  Specific activation of the non‐classical class I histocompatibility HLA‐G antigen and expression of the ILT2 inhibitory receptor in human breast cancer , 2002, The Journal of pathology.

[10]  J. Dausset,et al.  Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule , 2002, AIDS.

[11]  R. Fauchet,et al.  Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. , 2002, Human immunology.

[12]  R. Dummer,et al.  HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. , 2002, Blood.

[13]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[14]  P. Vyas,et al.  Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .

[15]  J. Dausset,et al.  Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: A CD4+ T cell regulatory mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Chouaib,et al.  Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. , 2001, Cancer research.

[17]  K. Khosrotehrani,et al.  HLA-G expression in atopic dermatitis. , 2001, The Journal of investigative dermatology.

[18]  M. Kurrer,et al.  Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. , 2001, The American journal of pathology.

[19]  S. Ugurel,et al.  Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon‐α immunotherapy , 2001 .

[20]  L. Dubertret,et al.  HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? , 2001, The American journal of pathology.

[21]  A. Merlo,et al.  Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. , 2000, Human immunology.

[22]  J. Dausset,et al.  Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. , 2000, Human immunology.

[23]  P. J. van den Elsen,et al.  Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. , 2000, Human immunology.

[24]  G. Ferrara,et al.  HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. , 2000, Human immunology.

[25]  Margaret A. Johnson,et al.  Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA‐G , 2000, Annals of neurology.

[26]  S. Wagner,et al.  Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma , 2000, The Lancet.

[27]  J. Dausset,et al.  Implication of HLA-G molecule in heart-graft acceptance , 2000, The Lancet.

[28]  P. André,et al.  Modulation of HLA-G Antigens Expression by Human Cytomegalovirus: Specific Induction in Activated Macrophages Harboring Human Cytomegalovirus Infection1 , 2000, The Journal of Immunology.

[29]  A. Toubert,et al.  Cutting Edge: Soluble HLA-G1 Triggers CD95/CD95 Ligand-Mediated Apoptosis in Activated CD8+ Cells by Interacting with CD81 , 2000, The Journal of Immunology.

[30]  J. Dausset,et al.  Polymorphism of HLA-G gene and protein. , 1999, Journal of reproductive immunology.

[31]  V. Guiard,et al.  Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. , 1999, Journal of reproductive immunology.

[32]  V. Guiard,et al.  © 1999 The Japanese Society for Immunology IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes , 2022 .

[33]  M. Colonna,et al.  The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA‐G1 and HLA‐E molecules co‐expressed on target cells , 1999, European journal of immunology.

[34]  S. Maier,et al.  Detection of soluble HLA-G molecules in plasma and amniotic fluid. , 1999, Tissue antigens.

[35]  M. Llano,et al.  HLA‐E‐bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA‐G‐derived nonamer , 1998, European journal of immunology.

[36]  B. Drénou,et al.  HLA-G class I gene expression in normal and malignant hematopoietic cells. , 1998, Human immunology.

[37]  Michele Cilli,et al.  p49, a putative HLA class I‐specific inhibitory NK receptor belonging to the immunoglobulin superfamily , 1998, European journal of immunology.

[38]  M. Llano,et al.  HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Dausset,et al.  HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Geraghty,et al.  Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA‐G , 1997, European journal of immunology.

[41]  J. Dausset,et al.  Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Hammer,et al.  HLA Class I Expression on the Materno‐Fetal Interface , 1997, American journal of reproductive immunology.

[43]  S. Fisher,et al.  Identification of a Thymic Epithelial Cell Subset Sharing Expression of the Class Ib HLA-G Molecule with Fetal Trophoblasts , 1997, The Journal of experimental medicine.

[44]  J. Dausset,et al.  The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Drénou,et al.  DISTRIBUTION OF HLA‐G ALTERNATIVE mRNAs INCLUDING SOLUBLE FORMS IN NORMAL LYMPHOCYTES AND IN LYMPHOID CELL‐DERIVED LEUKEMIA , 1996, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[46]  B. Drénou,et al.  HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. , 1996, Tissue antigens.

[47]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[48]  D. Geraghty,et al.  A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. , 1994, Journal of immunology.

[49]  J. Dausset,et al.  An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  N. Holmes,et al.  Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. , 1994, Cellular immunology.

[51]  M. Peuchmaur,et al.  In vivo production of interleukin‐10 by malignant cells in AIDS lymphomas , 1992, European journal of immunology.

[52]  D. Geraghty,et al.  Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Fisher,et al.  A class I antigen, HLA-G, expressed in human trophoblasts. , 1990, Science.

[54]  R. Bataille,et al.  Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. , 1983, British journal of haematology.

[55]  R. Bataille,et al.  Serum beta-2-microglobulin binding activity in monoclonal gammopathy: correlative study and clinical significance. , 1983, European journal of cancer & clinical oncology.